The FDA approved nemolizumab (Nemluvio) in combination with prescription topical agents for the treatment of moderate-to-severe atopic dermatitis, drugmaker Galderma announced. A monoclonal ...

The Chronic Pruritus Market is making significant strides, fueled by innovative treatment approaches and ongoing research ...

The FDA has approved these four biologics to treat atopic dermatitis: dupilumab, lebrikizumab, nemolizumab, and tralokinumab. They are all types of biologics called monoclonal antibodies.

The ruxolitinib cream met its primary end point as a treatment for prurigo nodularis in one phase 3 trial but fell short in ...

Dermatology specialist Galderma has claimed a second FDA approval for IL-31 inhibitor Nemluvio, adding atopic dermatitis to its label. Nemluvio (nemolizumab) – which was approved by the FDA in ...

Nemolizumab is approved for use alongside topical therapies ... new active substance work-sharing initiative procedure. The drug has also been approved in the European Union, the United States ...

The European Commission has approved nemolizumab (Nemluvio) for subcutaneous use in treating moderate to severe atopic dermatitis (AD) in patients aged ≥ 12 years and moderate to severe prurigo ...

Nemluvio is also approved by the U.S. Food and Drug Administration for the treatment ... trials evaluated the efficacy and safety of nemolizumab administered subcutaneously every four weeks ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine nemolizumab (brand name Nemluvio) for the treatment of two skins conditions – moderate to severe prurigo ...